拉克替醇联合思密达治疗病毒性肝炎患者的临床疗效及其对血清胆红素和内毒素水平的影响研究

Clinical Efficacy of Lactitol Combined with Smecta Treatment of Viral Hepatitis Patients and Its Influence of Serum Bilirubin and Endotoxin Levels

目的探讨拉克替醇联合思密达治疗病毒性肝炎患者的临床疗效及其对血清胆红素及内毒素水平的影响。方法选取2014年5月—2016年5月中国人民解放军第302医院收治的病毒性肝炎患者80例,采用随机数字表法分为拉克替醇联合思密达治疗组(联合治疗组,n=40)和常规保肝降酶袪黄治疗组(常规治疗组,n=40),观察两组患者的临床疗效,治疗前后分别测定两组患者血清胆红素及内毒素水平。结果联合治疗组患者临床疗效优于常规治疗组,差异有统计学意义(P<0.05)。两组患者治疗后血清胆红素及内毒素水平均低于治疗前,差异有统计学意义(P<0.05)。治疗前,两组患者血清胆红素及内毒素水平比较,差异无统计学意义(P>0.05);治疗后,联合治疗组患者血清胆红素及内毒素水平低于常规治疗组,差异有统计学意义(P<0.05)。结论拉克替醇联合思密达治疗能够有效提高病毒性肝炎患者的临床疗效,降低其血清胆红素及内毒素水平。

Objective To investigate the clinical efficacy of lactitol combined with smecta treatment of viral hepatitis patients, and its influence of serum bilirubin and endotoxin levels. Methods 80 cases of viral hepatitis patients who were treated in 302 Military Hospital of China from May 2014 to May 2016 were selected, these patients were divided into lactitol combined with smecta therapy group （combined treatment group, n = 4 0 ） and conventional liver Jiangmei Quhuang treatment group （ conventional treatment group, n =40） according to the random number table. The clinical efficacy, serum bilirubin and endotoxin levels before and after treatment of the two groups were statistically analyzed. Results The difference of therapeutic effect between two groups was statistically significant （P 〈 0. 05 ）. The serum bilirubin and endotoxin levels after treatment of the two groups were significantly lower than before treatment （ P 〈 0. 05 ）. The differences of serum bilirubin and endotoxin levels before treatment between the two groups were not significant （P 〉 0. 05 ） , the serum bilirubin and endotoxin levels after treatment in the combined treatment group were significantly lower than that in conventional treatment group （ P 〈 0. 05 ）. Conclusion The clinical efficacy of lactitol combined with smecta treatment of viral hepatitis patients is effectively improve, and serum bilirubin and endotoxin levels are reduce.